{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:39:24Z","timestamp":1792787964552,"version":"4.5.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T00:00:00Z","timestamp":1625443200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2018ZX09721003"],"award-info":[{"award-number":["2018ZX09721003"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013076","name":"National Major Science and Technology Projects of China","doi-asserted-by":"publisher","award":["2018ZX09711001"],"award-info":[{"award-number":["2018ZX09711001"]}],"id":[{"id":"10.13039\/501100013076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["3332019069"],"award-info":[{"award-number":["3332019069"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"name":"CAMS Innovation Fund for Medical Sciences","award":["201912M-I-005"],"award-info":[{"award-number":["201912M-I-005"]}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["7212155"],"award-info":[{"award-number":["7212155"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Standard chemotherapy with taxanes, such as paclitaxel (PTX), remains the mainstay of systemic treatment of triple-negative breast cancer. Nanotechnology-based formulations have gradually replaced PTX injection and are widely used in China. However, no studies have compared the colloidal stability, antitumor efficacy, and safety of commercial PTX nanoformulations. Additionally, the desire to evaluate preclinical antitumor efficacy in human-derived tumor cells led to the widespread application of immunodeficient mouse models that likely contributed to the neglect of nanomedicines-immune system interactions. The present study investigated the colloidal stability, antitumor efficacy and safety, and nanomedicines-host immune system interactions of PTX nanoformulations. A further comparative analysis was performed to evaluate the clinical potential.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Compared with liposome, PTX emulsion and PTX nanoparticle exhibited favorable colloidal stability. PTX emulsion was superior in inducing apoptosis and had a more pronounced inhibitory effect on 4T1-tumor spheroids compared with PTX liposome and PTX nanoparticle. Although PTX emulsion exhibited superior in vitro antitumor effect, no significant differences in the in vivo antitumor efficacy were found among the three types of PTX nanoformulations in an immunocompetent orthotopic 4T1 murine triple-negative breast cancer model. All PTX nanoformulations at maximum tolerated dose (MTD) induced lymphopenia and immunosuppression, as evidenced by the reduction of T cell subpopulations and inhibition of the dendritic cells maturation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The MTD PTX nanomedicines-induced lymphopenia and immunosuppression may weaken the lymphocyte-mediated antitumor cellular immune response and partly account for the lack of differences in the in vivo antitumor outcomes of PTX nanoformulations. Understanding of what impacts PTX nanomedicines has on the immune system may be critical to improve the design and conduct of translational research of PTX nanomedicines in monotherapy or combination therapy with immunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Graphic abstract<\/jats:title>\n                  <\/jats:sec>","DOI":"10.1186\/s12951-021-00946-w","type":"journal-article","created":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T06:04:33Z","timestamp":1625465073000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":30,"title":["Comparative colloidal stability, antitumor efficacy, and immunosuppressive effect of commercial paclitaxel nanoformulations"],"prefix":"10.1186","volume":"19","author":[{"given":"Jun","family":"Ye","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renjie","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanfang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wujun","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongliang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiqi","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caiyun","family":"Qin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyan","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengfeng","family":"Liao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiqun","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejun","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,5]]},"reference":[{"key":"946_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209.","journal-title":"CA Cancer J Clin"},{"key":"946_CR2","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","volume":"22","author":"L Yin","year":"2020","unstructured":"Yin L, Duan J-J, Bian X-W. Yu S-c: Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 2020;22:61.","journal-title":"Breast Cancer Res"},{"key":"946_CR3","doi-asserted-by":"publisher","first-page":"S142","DOI":"10.3747\/co.25.3954","volume":"25","author":"JM Lebert","year":"2018","unstructured":"Lebert JM, Lester R, Powell E, Seal M, McCarthy J. Advances in the systemic treatment of triple-negative breast cancer. Curr Oncol. 2018;25:S142\u201350.","journal-title":"Curr Oncol"},{"key":"946_CR4","doi-asserted-by":"publisher","first-page":"438","DOI":"10.3322\/caac.21583","volume":"69","author":"CE DeSantis","year":"2019","unstructured":"DeSantis CE, Ma J, Gaudet MM, Newman LA, Miller KD, Goding Sauer A, Jemal A, Siegel RL. Breast cancer statistics, 2019. CA Cancer J Clin. 2019;69:438\u201351.","journal-title":"CA Cancer J Clin"},{"key":"946_CR5","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1016\/j.phrs.2016.07.023","volume":"111","author":"AK Bakrania","year":"2016","unstructured":"Bakrania AK, Variya BC, Patel SS. Novel targets for paclitaxel nano formulations: hopes and hypes in triple negative breast cancer. Pharmacol Res. 2016;111:577\u201391.","journal-title":"Pharmacol Res"},{"key":"946_CR6","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1056\/NEJM199504133321507","volume":"332","author":"EK Rowinsky","year":"1995","unstructured":"Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med. 1995;332:1004\u201314.","journal-title":"N Engl J Med"},{"key":"946_CR7","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.addr.2017.02.003","volume":"122","author":"AM Sofias","year":"2017","unstructured":"Sofias AM, Dunne M, Storm G, Allen C. The battle of \u201cnano\u201d paclitaxel. Adv Drug Deliv Rev. 2017;122:20\u201330.","journal-title":"Adv Drug Deliv Rev"},{"key":"946_CR8","doi-asserted-by":"publisher","first-page":"7794","DOI":"10.1200\/JCO.2005.04.937","volume":"23","author":"WJ Gradishar","year":"2005","unstructured":"Gradishar WJ, Tjulandin S, Davidson N, Shaw H, Desai N, Bhar P, Hawkins M, O\u2019Shaughnessy J. Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol. 2005;23:7794\u2013803.","journal-title":"J Clin Oncol"},{"key":"946_CR9","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.jconrel.2016.01.034","volume":"225","author":"P Fonte","year":"2016","unstructured":"Fonte P, Reis S, Sarmento B. Facts and evidences on the lyophilization of polymeric nanoparticles for drug delivery. J Control Release. 2016;225:75\u201386.","journal-title":"J Control Release"},{"key":"946_CR10","unstructured":"Center for Drug Evaluation, National Medical Products Administration, China. http:\/\/www.cde.org.cn\/."},{"key":"946_CR11","doi-asserted-by":"publisher","first-page":"399","DOI":"10.3892\/or.2016.4787","volume":"36","author":"J Ye","year":"2016","unstructured":"Ye J, Liu Y, Xia X, Meng L, Dong W, Wang R, Fu Z, Liu H, Han R. Improved safety and efficacy of a lipid emulsion loaded with a paclitaxel-cholesterol complex for the treatment of breast tumors. Oncol Rep. 2016;36:399\u2013409.","journal-title":"Oncol Rep"},{"key":"946_CR12","doi-asserted-by":"publisher","first-page":"4125","DOI":"10.2147\/IJN.S113638","volume":"11","author":"J Ye","year":"2016","unstructured":"Ye J, Xia X, Dong W, Hao H, Meng L, Yang Y, Wang R, Lyu Y, Liu Y. Cellular uptake mechanism and comparative evaluation of antineoplastic effects of paclitaxel-cholesterol lipid emulsion on triple-negative and non-triple-negative breast cancer cell lines. Int J Nanomed. 2016;11:4125\u201340.","journal-title":"Int J Nanomed"},{"key":"946_CR13","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1021\/acsnano.6b08244","volume":"11","author":"TJ Anchordoquy","year":"2017","unstructured":"Anchordoquy TJ, Barenholz Y, Boraschi D, Chorny M, Decuzzi P, Dobrovolskaia MA, Farhangrazi ZS, Farrell D, Gabizon A, Ghandehari H, et al. Mechanisms and barriers in cancer nanomedicine: addressing challenges. Look Solut ACS Nano. 2017;11:12\u20138.","journal-title":"Look Solut ACS Nano"},{"key":"946_CR14","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1016\/j.jconrel.2016.04.028","volume":"232","author":"GH Petersen","year":"2016","unstructured":"Petersen GH, Alzghari SK, Chee W, Sankari SS, La-Beck NM. Meta-analysis of clinical and preclinical studies comparing the anticancer efficacy of liposomal versus conventional non-liposomal doxorubicin. J Control Release. 2016;232:255\u201364.","journal-title":"J Control Release"},{"key":"946_CR15","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.jconrel.2017.12.023","volume":"271","author":"R Rajan","year":"2018","unstructured":"Rajan R, Sabnani MK, Mavinkurve V, Shmeeda H, Mansouri H, Bonkoungou S, Le AD, Wood LM, Gabizon AA, La-Beck NM. Liposome-induced immunosuppression and tumor growth is mediated by macrophages and mitigated by liposome-encapsulated alendronate. J Control Release. 2018;271:139\u201348.","journal-title":"J Control Release"},{"key":"946_CR16","doi-asserted-by":"publisher","first-page":"416","DOI":"10.3389\/fimmu.2017.00416","volume":"8","author":"NM La-Beck","year":"2017","unstructured":"La-Beck NM, Gabizon AA. Nanoparticle interactions with the immune system: clinical implications for liposome-based cancer chemotherapy. Front Immunol. 2017;8:416.","journal-title":"Front Immunol"},{"key":"946_CR17","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1186\/s12951-020-00741-z","volume":"18","author":"A Bahreyni","year":"2020","unstructured":"Bahreyni A, Mohamud Y, Luo H. Emerging nanomedicines for effective breast cancer immunotherapy. J Nanobiotechnol. 2020;18:180.","journal-title":"J Nanobiotechnol"},{"key":"946_CR18","doi-asserted-by":"publisher","first-page":"479","DOI":"10.6004\/jnccn.2020.7554","volume":"18","author":"TE Keenan","year":"2020","unstructured":"Keenan TE, Tolaney SM. Role of immunotherapy in triple-negative breast cancer. J Natl Compr Canc Netw. 2020;18:479.","journal-title":"J Natl Compr Canc Netw"},{"key":"946_CR19","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1186\/s12885-017-3677-7","volume":"17","author":"WJ Aston","year":"2017","unstructured":"Aston WJ, Hope DE, Nowak AK, Robinson BW, Lake RA, Lesterhuis WJ. A systematic investigation of the maximum tolerated dose of cytotoxic chemotherapy with and without supportive care in mice. BMC Cancer. 2017;17:684.","journal-title":"BMC Cancer"},{"key":"946_CR20","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1182\/blood.V84.7.2221.2221","volume":"84","author":"C Mackall","year":"1994","unstructured":"Mackall C, Fleisher T, Brown M, Magrath I, Shad A, Horowitz M, Wexler L, Adde M, McClure L, Gress R. Lymphocyte depletion during treatment with intensive chemotherapy for cancer. Blood. 1994;84:2221\u20138.","journal-title":"Blood"},{"key":"946_CR21","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1186\/1471-2407-13-177","volume":"13","author":"H Chu-Yuan","year":"2013","unstructured":"Chu-Yuan H, Jing P, Yi-Sheng W, He-Ping P, Hui Y, Chu-Xiong Z, Guo-Jian L, Guo-Qiang W. The impact of chemotherapy-associated neutrophil\/lymphocyte counts on prognosis of adjuvant chemotherapy in colorectal cancer. BMC Cancer. 2013;13:177.","journal-title":"BMC Cancer"},{"key":"946_CR22","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1007\/s11060-017-2668-5","volume":"136","author":"AJ Lin","year":"2018","unstructured":"Lin AJ, Campian JL, Hui C, Rudra S, Rao YJ, Thotala D, Hallahan D, Huang J. Impact of concurrent versus adjuvant chemotherapy on the severity and duration of lymphopenia in glioma patients treated with radiation therapy. J Neurooncol. 2018;136:403\u201311.","journal-title":"J Neurooncol"},{"key":"946_CR23","first-page":"420","volume":"31","author":"L Borella","year":"1971","unstructured":"Borella L, Webster RG. The immunosuppressive effects of long-term combination chemotherapy in children with acute leukemia in remission. Can Res. 1971;31:420.","journal-title":"Can Res"},{"key":"946_CR24","doi-asserted-by":"publisher","first-page":"5473","DOI":"10.1158\/1078-0432.CCR-11-0774","volume":"17","author":"SA Grossman","year":"2011","unstructured":"Grossman SA, Ye X, Lesser G, Sloan A, Carraway H, Desideri S, Piantadosi S. Immunosuppression in patients with high-grade gliomas treated with radiation and temozolomide. Clin Cancer Res. 2011;17:5473.","journal-title":"Clin Cancer Res"},{"key":"946_CR25","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1016\/j.ijrobp.2015.04.005","volume":"92","author":"J Huang","year":"2015","unstructured":"Huang J, DeWees TA, Badiyan SN, Speirs CK, Mullen DF, Fergus S, Tran DD, Linette G, Campian JL, Chicoine MR, et al. Clinical and dosimetric predictors of acute severe lymphopenia during radiation therapy and concurrent temozolomide for high-grade glioma. Int J Radiat Oncol Biol Phys. 2015;92:1000\u20137.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"946_CR26","doi-asserted-by":"publisher","first-page":"819","DOI":"10.3390\/cancers12040819","volume":"12","author":"A Diana","year":"2020","unstructured":"Diana A, Carlino F, Franzese E, Oikonomidou O, Criscitiello C, De Vita F, Ciardiello F, Orditura M. Early triple negative breast cancer: conventional treatment and emerging therapeutic landscapes. Cancers. 2020;12:819.","journal-title":"Cancers"},{"key":"946_CR27","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1158\/1078-0432.CCR-05-1634","volume":"12","author":"N Desai","year":"2006","unstructured":"Desai N, Trieu V, Yao Z, Louie L, Ci S, Yang A, Tao C, De T, Beals B, Dykes D, et al. Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremophor-based paclitaxel. Clin Cancer Res. 2006;12:1317.","journal-title":"Clin Cancer Res"},{"key":"946_CR28","doi-asserted-by":"publisher","first-page":"947","DOI":"10.3892\/mmr.2013.1264","volume":"7","author":"H Wang","year":"2013","unstructured":"Wang H, Cheng G, Du Y, Ye L, Chen W, Zhang L, Wang T, Tian J, Fu F. Hypersensitivity reaction studies of a polyethoxylated castor oil-free, liposome-based alternative paclitaxel formulation. Mol Med Rep. 2013;7:947\u201352.","journal-title":"Mol Med Rep"},{"key":"946_CR29","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.2217\/nnm.10.75","volume":"5","author":"MS Muthu","year":"2010","unstructured":"Muthu MS, Feng S-S. Nanopharmacology of liposomes developed for cancer therapy. Nanomedicine. 2010;5:1017\u20139.","journal-title":"Nanomedicine"},{"key":"946_CR30","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.bioactmat.2020.05.001","volume":"5","author":"J Ye","year":"2020","unstructured":"Ye J, Yang Y, Jin J, Ji M, Gao Y, Feng Y, Wang H, Chen X, Liu Y. Targeted delivery of chlorogenic acid by mannosylated liposomes to effectively promote the polarization of TAMs for the treatment of glioblastoma. Bioact Mater. 2020;5:694\u2013708.","journal-title":"Bioact Mater"},{"key":"946_CR31","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1007\/s11095-017-2141-3","volume":"34","author":"J Ye","year":"2017","unstructured":"Ye J, Dong W, Yang Y, Hao H, Liao H, Wang B, Han X, Jin Y, Xia X, Liu Y. Vitamin E-rich nanoemulsion enhances the antitumor efficacy of low-dose paclitaxel by driving Th1 immune response. Pharm Res. 2017;34:1244\u201354.","journal-title":"Pharm Res"},{"key":"946_CR32","doi-asserted-by":"publisher","first-page":"1785","DOI":"10.1038\/s41598-018-20243-1","volume":"8","author":"M Bermudez-Brito","year":"2018","unstructured":"Bermudez-Brito M, Borghuis T, Daniel C, Pot B, de Haan BJ, Faas MM, de Vos P. L. plantarum WCFS1 enhances Treg frequencies by activating DCs even in absence of sampling of bacteria in the peyer patches. Sci Rep. 2018;8:1785\u20131785.","journal-title":"Sci Rep"},{"key":"946_CR33","doi-asserted-by":"publisher","first-page":"5294","DOI":"10.1182\/blood-2011-11-391680","volume":"119","author":"A Wroblewska","year":"2012","unstructured":"Wroblewska A, van Haren SD, Herczenik E, Kaijen P, Ruminska A, Jin S-Y, Zheng XL, van den Biggelaar M, ten Brinke A, Meijer AB, Voorberg J. Modification of an exposed loop in the C1 domain reduces immune responses to factor VIII in hemophilia A mice. Blood. 2012;119:5294\u2013300.","journal-title":"Blood"},{"key":"946_CR34","doi-asserted-by":"publisher","first-page":"5629","DOI":"10.2147\/IJN.S261162","volume":"15","author":"W Dong","year":"2020","unstructured":"Dong W, Ye J, Wang W, Yang Y, Wang H, Sun T, Gao L, Liu Y. Self-assembled lecithin\/chitosan nanoparticles based on phospholipid complex: a feasible strategy to improve entrapment efficiency and transdermal delivery of poorly lipophilic drug. Int J Nanomed. 2020;15:5629\u201343.","journal-title":"Int J Nanomed"},{"key":"946_CR35","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1517\/14656566.7.8.1041","volume":"7","author":"WJ Gradishar","year":"2006","unstructured":"Gradishar WJ. Albumin-bound paclitaxel: a next-generation taxane. Expert Opin Pharmacother. 2006;7:1041\u201353.","journal-title":"Expert Opin Pharmacother"},{"key":"946_CR36","doi-asserted-by":"publisher","first-page":"1263","DOI":"10.1093\/annonc\/mdl104","volume":"17","author":"MR Green","year":"2006","unstructured":"Green MR, Manikhas GM, Orlov S, Afanasyev B, Makhson AM, Bhar P, Hawkins MJ. Abraxane\u00ae, a novel Cremophor\u00ae-free, albumin-bound particle form of paclitaxel for the treatment of advanced non-small-cell lung cancer. Ann Oncol. 2006;17:1263\u20138.","journal-title":"Ann Oncol"},{"key":"946_CR37","first-page":"1314","volume":"65","author":"V Trieu","year":"2005","unstructured":"Trieu V, Frankel T, Labao E, Soon-Shiong P, Desai N. SPARC expression in breast tumors may correlate to increased tumor distribution of nanoparticle albumin-bound paclitaxel (ABI-007) vs taxol. Can Res. 2005;65:1314.","journal-title":"Can Res"},{"key":"946_CR38","doi-asserted-by":"publisher","first-page":"1736","DOI":"10.1183\/09031936.96.09081736","volume":"9","author":"M Drent","year":"1996","unstructured":"Drent M, Cobben NA, Henderson RF, Wouters EF, van Dieijen-Visser M. Usefulness of lactate dehydrogenase and its isoenzymes as indicators of lung damage or inflammation. Eur Respir J. 1996;9:1736.","journal-title":"Eur Respir J"},{"key":"946_CR39","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1186\/s13058-015-0669-x","volume":"18","author":"R Verma","year":"2016","unstructured":"Verma R, Foster RE, Horgan K, Mounsey K, Nixon H, Smalle N, Hughes TA, Carter CRD. Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer. Breast Cancer Res. 2016;18:10.","journal-title":"Breast Cancer Res"},{"key":"946_CR40","doi-asserted-by":"publisher","first-page":"862","DOI":"10.1200\/JCO.1999.17.3.862","volume":"17","author":"C Kouroussis","year":"1999","unstructured":"Kouroussis C, Androulakis N, Kakolyris S, Souglakos J, Kotsakis T, Mavroudis D, Katsogridakis K, Vardakis N, Hatzidaki D, Samonis G, et al. Dose-escalation study of docetaxel in combination with mitoxantrone as first-line treatment in patients with metastatic breast cancer. J Clin Oncol. 1999;17:862.","journal-title":"J Clin Oncol"},{"key":"946_CR41","doi-asserted-by":"publisher","first-page":"1380","DOI":"10.1002\/1097-0142(20000915)89:6<1380::AID-CNCR23>3.0.CO;2-R","volume":"89","author":"A Kotsakis","year":"2000","unstructured":"Kotsakis A, Sarra E, Peraki M, Koukourakis M, Apostolaki S, Souglakos J, Mavromanomakis E, Vlachonikolis J, Georgoulias V. Docetaxel-induced lymphopenia in patients with solid tumors. Cancer. 2000;89:1380\u20136.","journal-title":"Cancer"},{"key":"946_CR42","doi-asserted-by":"publisher","first-page":"5627","DOI":"10.1016\/j.biomaterials.2010.03.067","volume":"31","author":"V Sokolova","year":"2010","unstructured":"Sokolova V, Knuschke T, Kovtun A, Buer J, Epple M, Westendorf AM. The use of calcium phosphate nanoparticles encapsulating Toll-like receptor ligands and the antigen hemagglutinin to induce dendritic cell maturation and T cell activation. Biomaterials. 2010;31:5627\u201333.","journal-title":"Biomaterials"},{"key":"946_CR43","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/s41467-019-14230-x","volume":"11","author":"Y-J Lin","year":"2020","unstructured":"Lin Y-J, Wen C-N, Lin Y-Y, Hsieh W-C, Chang C-C, Chen Y-H, Hsu C-H, Shih Y-J, Chen C-H, Fang C-T. Oil-in-water emulsion adjuvants for pediatric influenza vaccines: a systematic review and meta-analysis. Nat Commun. 2020;11:315.","journal-title":"Nat Commun"},{"key":"946_CR44","doi-asserted-by":"publisher","first-page":"42","DOI":"10.3390\/vaccines7020042","volume":"7","author":"L Louis","year":"2019","unstructured":"Louis L, Wise MC, Choi H, Villarreal DO, Muthumani K, Weiner DB. Designed DNA-encoded IL-36 gamma acts as a potent molecular adjuvant enhancing zika synthetic DNA vaccine-induced immunity and protection in a lethal challenge model. Vaccines. 2019;7:42.","journal-title":"Vaccines"},{"key":"946_CR45","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1007\/s10549-009-0594-8","volume":"122","author":"CJ Antalis","year":"2010","unstructured":"Antalis CJ, Arnold T, Rasool T, Lee B, Buhman KK, Siddiqui RA. High ACAT1 expression in estrogen receptor negative basal-like breast cancer cells is associated with LDL-induced proliferation. Breast Cancer Res Treat. 2010;122:661\u201370.","journal-title":"Breast Cancer Res Treat"},{"key":"946_CR46","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1158\/0008-5472.CAN-12-2225","volume":"73","author":"C-L Chang","year":"2013","unstructured":"Chang C-L, Hsu Y-T, Wu C-C, Lai Y-Z, Wang C, Yang Y-C, Wu TC, Hung C-F. Dose-dense chemotherapy improves mechanisms of antitumor immune response. Can Res. 2013;73:119.","journal-title":"Can Res"},{"key":"946_CR47","doi-asserted-by":"publisher","first-page":"e11416","DOI":"10.15252\/emmm.201911416","volume":"12","author":"L Schito","year":"2020","unstructured":"Schito L, Rey S, Xu P, Man S, Cruz-Mu\u00f1oz W, Kerbel RS. Metronomic chemotherapy offsets HIF\u03b1 induction upon maximum-tolerated dose in metastatic cancers. EMBO Mol Med. 2020;12:e11416.","journal-title":"EMBO Mol Med"},{"key":"946_CR48","doi-asserted-by":"publisher","first-page":"e111906","DOI":"10.1371\/journal.pone.0111906","volume":"9","author":"X Zhang","year":"2014","unstructured":"Zhang X, Zhang W, Feng L-J. : Prognostic significance of neutrophil lymphocyte ratio in patients with gastric cancer: a meta-analysis. PLoS ONE. 2014;9:e111906.","journal-title":"PLoS ONE"},{"key":"946_CR49","doi-asserted-by":"publisher","first-page":"3387","DOI":"10.1016\/j.ejca.2013.06.038","volume":"49","author":"K Lien","year":"2013","unstructured":"Lien K, Georgsdottir S, Sivanathan L, Chan K, Emmenegger U. Low-dose metronomic chemotherapy: a systematic literature analysis. Eur J Cancer. 2013;49:3387\u201395.","journal-title":"Eur J Cancer"},{"key":"946_CR50","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.canlet.2014.12.039","volume":"358","author":"I Kareva","year":"2015","unstructured":"Kareva I, Waxman DJ, Lakka Klement G. Metronomic chemotherapy: an attractive alternative to maximum tolerated dose therapy that can activate anti-tumor immunity and minimize therapeutic resistance. Cancer Lett. 2015;358:100\u20136.","journal-title":"Cancer Lett"},{"key":"946_CR51","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.canlet.2017.01.040","volume":"400","author":"Y-L Chen","year":"2017","unstructured":"Chen Y-L, Chang M-C, Cheng W-F. Metronomic chemotherapy and immunotherapy in cancer treatment. Cancer Lett. 2017;400:282\u201392.","journal-title":"Cancer Lett"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-021-00946-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-021-00946-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-021-00946-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,5]],"date-time":"2021-07-05T06:09:44Z","timestamp":1625465384000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-021-00946-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,5]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["946"],"URL":"https:\/\/doi.org\/10.1186\/s12951-021-00946-w","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,5]]},"assertion":[{"value":"19 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures involving experimental animals were carried out under guidelines approved by the Institutional Animal Care and Use Committee of Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"199"}}